Figure 1
Figure 1. Conditioning regimen and schedule for CTL infusion. (A) The conditioning regimen used before allogeneic SCT. The regimen for patients 18 to 40 years of age consisted of hyperfractionated TBI with 6 × 200 cGy from day −9 to day −7, with lung shielding (maximum lung dose of 800 cGy). Patients older than 40 years received only 4 × 200 cGy. Fludarabine was infused at a daily dose of 40 mg/m2 from day −6 to day −2. On the same days, 5 mg/kg antithymocyte globulin (ATG)–Fresenius was infused over 4 hours. Two doses of thiotepa (5 mg/kg) were infused over 4 hours on day −5. Treatment with cyclosporine A was initiated on day −10 at a daily dose of 1 mg/kg until day −3. CD34+-selected peripheral blood stem cells were infused on day 0 (SCT). (B) The planned schedule of infusion of in vitro-generated CD8+ T-cell preparations. Whenever possible, in vitro-cultured donor CD8+ T cells were infused on days 28, 56, and 112. No postgrafting immunosuppressive therapy was administered.

Conditioning regimen and schedule for CTL infusion. (A) The conditioning regimen used before allogeneic SCT. The regimen for patients 18 to 40 years of age consisted of hyperfractionated TBI with 6 × 200 cGy from day −9 to day −7, with lung shielding (maximum lung dose of 800 cGy). Patients older than 40 years received only 4 × 200 cGy. Fludarabine was infused at a daily dose of 40 mg/m2 from day −6 to day −2. On the same days, 5 mg/kg antithymocyte globulin (ATG)–Fresenius was infused over 4 hours. Two doses of thiotepa (5 mg/kg) were infused over 4 hours on day −5. Treatment with cyclosporine A was initiated on day −10 at a daily dose of 1 mg/kg until day −3. CD34+-selected peripheral blood stem cells were infused on day 0 (SCT). (B) The planned schedule of infusion of in vitro-generated CD8+ T-cell preparations. Whenever possible, in vitro-cultured donor CD8+ T cells were infused on days 28, 56, and 112. No postgrafting immunosuppressive therapy was administered.

Close Modal

or Create an Account

Close Modal
Close Modal